Chavarin P, DePutter C, Boussoulade F, Acquart S, Vidal M, Argaud C, Fabrigli P, Garraud O
Établissement français du sang Auvergne-Loire, Saint-Étienne, France.
Transfus Clin Biol. 2011 Aug;18(4):472-7. doi: 10.1016/j.tracli.2011.04.002. Epub 2011 Jul 23.
In the past few years, pathogen reduction technologies for labile blood products have been part of the enhancement of global transfusion safety regarding residual risks of transmitting infectious pathogens. Having carried out a feasibility study for the implementation of pathogen inactivation of platelet concentrates by means of the amotosalen/HCl/UVA (Intercept™) technology, and participated to a reinforced haemovigilance study, we took the opportunity to analyze the organization consequences for platelet concentrates inventory and distribution. This impact study first indicated that those novel needs forced the blood donation service, as well as the labile blood product preparation laboratory, to review and improve practices; secondly, it showed that the routine implementation has little (no major) consequence in the overall organization, independently of the economic consequences (not covered here).
在过去几年中，针对易变血液制品的病原体灭活技术已成为提升全球输血安全、降低传染性病原体残留风险工作的一部分。我们通过开展一项关于采用氨甲环酸/盐酸/紫外线A（Intercept™）技术对血小板浓缩物进行病原体灭活的可行性研究，并参与了一项强化血液监测研究，借此机会分析了血小板浓缩物库存和分发方面的组织影响。这项影响研究首先表明，这些新需求促使献血服务机构以及易变血液制品制备实验室审查并改进操作流程；其次，研究表明，常规实施在整体组织中几乎没有（没有重大）影响，与经济影响无关（此处未涉及）。
